Literature DB >> 48406

Changes in brain hydrolytic enzyme activities in rats treated with cholesterol biosynthesis inhibitor, AY9944.

M Igarashi, K Suzuki, S M Chen.   

Abstract

Intraperitoneal administration of AY9944 causes accumulation of 7-dehydrocholesterol, appearance of abnormal neuronal cytoplasmic lamellar inclusions containing acid phosphatase activities, and degeneration of oligodendroglial cells. In the present study, we attempted to correlate appearance and disappearance of abnormal inclusions, oligodendroglial degeneration, activities of lysosomal enzymes, and accumulation of 7-dehydrocholesterol. One group of 5-day-old rats received daily injection of AY9944, 30 mg/kg, for 30 days. Other groups received the same daily dosage but only in 10 consecutive days, starting from 5, 15, 25, and 35 days, respectively. Activities of 13 brain hydrolytic enzymes were determined. In the first group, activities of most enzymes increased over the controls, reaching the peak between the 15th and 25th day, corresponding to the maximum appearance of the neuronal inclusions and degenerating oligodendroglia. Despite the continued administration of AY9944 and the high tissue concentration of 7-dehydrocholesterol, activities of most enzymes declined after 25 days to relatively steady levels somewhat higher than controls. In the group which received 10-day injections, enzyme activities reached the peak at the end of the injections and then rapidly returned to normal within 10 days thereafter, corresponding to the appearance and disappearance of the abnormal inclusions. However, 7-dehydrocholesterol continued to increase for 10 days after the drug administration was discontinued. AY9944 had no direct effect on any of the enzymes in vitro. There appears to be generalized lysosomal activation concomitant with formation of abnormal neuronal inclusions in the experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48406     DOI: 10.1016/0006-8993(75)90685-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome.

Authors:  G J Patti; L P Shriver; C A Wassif; H K Woo; W Uritboonthai; J Apon; M Manchester; F D Porter; G Siuzdak
Journal:  Neuroscience       Date:  2010-07-27       Impact factor: 3.590

2.  The biochemical and morphological response of hydrolytic enzymes in the developing brain to hypocholesterolemic agents.

Authors:  R B Ramsey; V W Fischer
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

Review 3.  Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network.

Authors:  Jan Skácel; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

4.  Effects of several lipidosis-including drugs upon the area postrema and adjacent medullary nuclei of adult rats. I. Alterations is perikarya and dendrites.

Authors:  W Frisch; R Lüllmann-Rauch
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

5.  Retinal degeneration in a rodent model of Smith-Lemli-Opitz syndrome: electrophysiologic, biochemical, and morphologic features.

Authors:  Steven J Fliesler; Neal S Peachey; Michael J Richards; Barbara A Nagel; Dana K Vaughan
Journal:  Arch Ophthalmol       Date:  2004-08

6.  Effects of trans-clomiphene in combination with AY-9944 on rat CNS morphology and biochemistry.

Authors:  R B Ramsey; V W Fischer
Journal:  Acta Neuropathol       Date:  1976-09-15       Impact factor: 17.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.